drugset / Trial / NCT04452370
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer
Timeline
- Start
- 2020-09-23
- Primary completion
- 2022-07-11
- Completion
- 2023-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Etoposide | Small molecule | 75 mg | Oral |